Perpetual Medicines and Third Rock Ventures Deliver a Development Candidate in Under 18 Months via Computational Physics and AI-Driven Platform
Perpetual Medicines, a biotechnology company pioneering the integration of computational physics and artificial intelligence for complex drug discovery, today announced the successful delivery of a development candidate in collaboration with Third Rock Ventures. The milestone was achieved in less than 18 months.
Perpetual Medicines Completes $8 Million Seed Round to Advance Integrated Computational Design-Synthesis Platform for Peptide Drug Discovery
Perpetual Medicines today announced it has closed an $8 million seed financing to advance its integrated computational design and synthesis platform for peptide drug discovery. The financing round was led by Chengwei Capital.
